Literature DB >> 26031671

Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges.

M Odette Gore1, Darren K McGuire, Ildiko Lingvay, Julio Rosenstock.   

Abstract

Type 2 diabetes mellitus has reached epidemic proportions around the world, and the increase in cardiovascular risk attributable to diabetes estimated to range from 2- to 4-fold poses grave public health concern. Though in some contexts type 2 diabetes has been equated with coronary heart disease equivalent risk, there is considerable evidence that incremental cardiovascular risk does not uniformly affect all people with type 2 diabetes. This heterogeneity in cardiovascular risk is multifactorial and only partially understood but is a key consideration for our understanding of the nexus of diabetes and cardiovascular disease and for the development of optimal and individualized cardiovascular risk reduction strategies. This review provides a brief synopsis of the concept of cardiovascular risk heterogeneity in diabetes, including epidemiologic evidence, discussion of established and potential determinants of heterogeneity, and clinical, research, and regulatory implications.

Entities:  

Mesh:

Year:  2015        PMID: 26031671     DOI: 10.1007/s11886-015-0607-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  78 in total

1.  Archimedes: a trial-validated model of diabetes.

Authors:  David M Eddy; Leonard Schlessinger
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.

Authors:  Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard
Journal:  J Am Coll Cardiol       Date:  2002-12-04       Impact factor: 24.094

4.  Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32).

Authors: 
Journal:  Diabetes Care       Date:  1998-08       Impact factor: 19.112

5.  Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin.

Authors:  Leah E Cahill; Andrew P Levy; Stephanie E Chiuve; Majken K Jensen; Hong Wang; Nawar M Shara; Shany Blum; Barbara V Howard; Jennifer K Pai; Kenneth J Mukamal; Kathryn M Rexrode; Eric B Rimm
Journal:  J Am Coll Cardiol       Date:  2013-01-09       Impact factor: 24.094

6.  Resequencing and clinical associations of the 9p21.3 region: a comprehensive investigation in the Framingham heart study.

Authors:  Andrew D Johnson; Shih-Jen Hwang; Arend Voorman; Alanna Morrison; Gina M Peloso; Yi-Hsiang Hsu; George Thanassoulis; Christopher Newton-Cheh; Ian S Rogers; Udo Hoffmann; Jane E Freedman; Caroline S Fox; Bruce M Psaty; Eric Boerwinkle; L Adrienne Cupples; Christopher J O'Donnell
Journal:  Circulation       Date:  2013-01-11       Impact factor: 29.690

7.  Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients.

Authors:  V M Connolly; C M Kesson
Journal:  Diabetes Care       Date:  1996-05       Impact factor: 19.112

8.  Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults.

Authors:  Rita Rastogi Kalyani; Mariana Lazo; Pamela Ouyang; Evrim Turkbey; Karinne Chevalier; Frederick Brancati; Diane Becker; Dhananjay Vaidya
Journal:  Diabetes Care       Date:  2013-10-31       Impact factor: 19.112

9.  The missed patient with diabetes: how access to health care affects the detection of diabetes.

Authors:  Xuanping Zhang; Linda S Geiss; Yiling J Cheng; Gloria L Beckles; Edward W Gregg; Henry S Kahn
Journal:  Diabetes Care       Date:  2008-09       Impact factor: 19.112

10.  Haptoglobin 2-2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck Study.

Authors:  Raimund Pechlaner; Stefan Kiechl; Peter Willeit; Egon Demetz; Margot Haun; Siegfried Weger; Friedrich Oberhollenzer; Florian Kronenberg; Enzo Bonora; Günter Weiss; Johann Willeit
Journal:  J Am Heart Assoc       Date:  2014-05-16       Impact factor: 5.501

View more
  13 in total

Review 1.  Cardiovascular Risk Heterogeneity in Adults with Diabetes: Selective Use of Coronary Artery Calcium in Statin Use Decision-making.

Authors:  Sudipa Sarkar; Olusola A Orimoloye; Caitlin M Nass; Roger S Blumenthal; Seth S Martin
Journal:  J Gen Intern Med       Date:  2019-08-14       Impact factor: 5.128

2.  Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome.

Authors:  Ilaria Cavallari; Ernesto Maddaloni; Felice Gragnano; Giuseppe Patti; Emilia Antonucci; Paolo Calabrò; Plinio Cirillo; Paolo Gresele; Gualtiero Palareti; Vittorio Pengo; Pasquale Pignatelli; Rossella Marcucci
Journal:  Intern Emerg Med       Date:  2021-02-22       Impact factor: 3.397

Review 3.  miR-33 in cardiometabolic diseases: lessons learned from novel animal models and approaches.

Authors:  Nathan L Price; Leigh Goedeke; Yajaira Suárez; Carlos Fernández-Hernando
Journal:  EMBO Mol Med       Date:  2021-05-03       Impact factor: 12.137

Review 4.  MicroRNAs and Circular RNAs in Lipoprotein Metabolism.

Authors:  Pablo Fernández-Tussy; Inmaculada Ruz-Maldonado; Carlos Fernández-Hernando
Journal:  Curr Atheroscler Rep       Date:  2021-05-10       Impact factor: 5.967

5.  The pleiotropic effects of metformin: time for prospective studies.

Authors:  Daniel I Bromage; Derek M Yellon
Journal:  Cardiovasc Diabetol       Date:  2015-08-14       Impact factor: 9.951

6.  Retinopathy Signs Improved Prediction and Reclassification of Cardiovascular Disease Risk in Diabetes: A prospective cohort study.

Authors:  Henrietta Ho; Carol Y Cheung; Charumathi Sabanayagam; Wanfen Yip; Mohammad Kamran Ikram; Peng Guan Ong; Paul Mitchell; Khuan Yew Chow; Ching Yu Cheng; E Shyong Tai; Tien Yin Wong
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

Review 7.  Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.

Authors:  Zhenghong Liu; Xiaoxuan Ma; Iqra Ilyas; Xueying Zheng; Sihui Luo; Peter J Little; Danielle Kamato; Amirhossein Sahebkar; Weiming Wu; Jianping Weng; Suowen Xu
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 8.  Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH.

Authors:  Leigh Goedeke; Gerald I Shulman
Journal:  Mol Metab       Date:  2021-02-03       Impact factor: 7.422

9.  CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation in the PREDIMED randomized trial.

Authors:  Dolores Corella; Eva M Asensio; Oscar Coltell; José V Sorlí; Ramón Estruch; Miguel Ángel Martínez-González; Jordi Salas-Salvadó; Olga Castañer; Fernando Arós; José Lapetra; Lluís Serra-Majem; Enrique Gómez-Gracia; Carolina Ortega-Azorín; Miquel Fiol; Javier Díez Espino; Andrés Díaz-López; Montserrat Fitó; Emilio Ros; José M Ordovás
Journal:  Cardiovasc Diabetol       Date:  2016-01-07       Impact factor: 9.951

Review 10.  Psychosocial Factors in Diabetes and Cardiovascular Risk.

Authors:  Ruth A Hackett; Andrew Steptoe
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.